Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.
Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.
Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
Produced by enzymatic breakdown of purified pig brain proteins, yielding a mixture of small peptides and amino acids. The claimed mechanism is neurotrophic activity mimicking endogenous factors such as BDNF and GDNF. Because the composition is a mixture rather than a defined entity, mechanistic claims are inherently imprecise, and batch consistency is a live scientific question rather than a manufacturing detail.
Substantially more human data than most neuropeptides here — trials in acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury, conducted largely in Europe, Russia and Asia. Cochrane reviews of stroke have concluded the evidence does not demonstrate benefit and have raised concerns about outcome reporting. It is registered in many countries and rejected by others, which tells you how the evidence reads to different regulators.
Not FDA-approved. Registered in numerous countries across Europe and Asia. Animal-derived biological material.
Extensive marketed use suggests reasonable tolerability. Porcine origin brings immunogenicity and transmissible-agent considerations that synthetic peptides do not have.
Trials used 10–30 mL IV daily courses (a defined-volume biological). Registered in many countries; Cochrane found no proven benefit in acute stroke.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.